$AML-399 A phase 2, open-label, multiarm, multicenter study to evaluate magrolimab combined with antileukemia therapies for first-line, relapsed/refractory, or maintenance treatment of acute myeloid leukemia (AML)$

AML-399 A phase 2, open-label, multiarm, multicenter study to evaluate magrolimab combined with antileukemia therapies for first-line, relapsed/refractory, or maintenance treatment of acute myeloid leukemia (AML)

Bibliographic Details
Main Authors:	Vyas, P, Daver, N, Chao, M, Xing, G, Renard, C, Ramsingh, G, Sallman, D
Format:	Conference item
Language:	English
Published:	Elsevier 2022

AML-399 A phase 2, open-label, multiarm, multicenter study to evaluate magrolimab combined with antileukemia therapies for first-line, relapsed/refractory, or maintenance treatment of acute myeloid leukemia (AML)

Similar Items